Henry Schein (NASDAQ:HSIC) Price Target Raised to $87.00 at UBS Group

Henry Schein (NASDAQ:HSIC) had its target price upped by analysts at UBS Group from $79.00 to $87.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price objective would indicate a potential upside of 6.19% from the stock’s current price.

Several other equities research analysts have also commented on HSIC. Mizuho upped their price objective on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research note on Wednesday. Leerink Partners upped their price target on Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a research report on Tuesday. Barclays began coverage on Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective on the stock. Morgan Stanley increased their target price on shares of Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a report on Wednesday. Finally, Evercore lifted their price target on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein Stock Performance

HSIC stock traded down $1.42 during trading on Wednesday, reaching $81.93. The stock had a trading volume of 1,681,765 shares, compared to its average volume of 1,397,827. The stock’s 50 day moving average is $77.56 and its two-hundred day moving average is $71.90. Henry Schein has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The firm has a market cap of $9.64 billion, a PE ratio of 25.90, a PEG ratio of 2.40 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The firm’s revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities analysts anticipate that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Trading of Henry Schein

Hedge funds have recently modified their holdings of the company. Artisan Partners Limited Partnership increased its position in Henry Schein by 5.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after purchasing an additional 370,837 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Henry Schein by 4.1% in the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after buying an additional 184,763 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Henry Schein by 8.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,816,317 shares of the company’s stock valued at $212,865,000 after buying an additional 220,149 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Henry Schein by 11.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after acquiring an additional 256,156 shares during the last quarter. Finally, Southpoint Capital Advisors LP grew its position in Henry Schein by 38.9% in the fourth quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock worth $188,950,000 after acquiring an additional 700,000 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Key Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 results beat expectations — EPS $1.34 vs $1.30 and revenue $3.44B vs $3.34B; company issued FY‑2026 guidance of $5.23–5.37 EPS and raised revenue guidance, which underpins the bullish analyst reactions. Reuters: Henry Schein beats quarterly profit estimates
• Positive Sentiment: JPMorgan raised its price target to $92 and set an “overweight” rating — a sizable upward revision that signals institutional confidence in growth after the quarter. TickerReport: JPMorgan raises PT on Henry Schein
• Positive Sentiment: Robert W. Baird upgraded HSIC to “outperform” and lifted its target to $100 — the most bullish call among recent analyst moves, adding upside sentiment. The Fly: Baird upgrades Henry Schein
• Neutral Sentiment: Mizuho, Wells Fargo and Leerink raised price targets (to $88, $87 and $87 respectively) but kept neutral/equal‑weight/market‑perform stances — supportive but not aggressively bullish. Benzinga: analyst updates
• Neutral Sentiment: Company provided FY‑2026 guidance roughly in line with consensus on EPS and slightly above on revenue — this reduces downside risk but leaves limited surprise to the upside. MarketBeat: Henry Schein earnings & guidance
• Negative Sentiment: Morgan Stanley and at least one analyst maintain a sell/underweight view with a low target (~$58–$61), highlighting margin pressure and valuation concerns that can limit buying interest despite the beat. TipRanks: Morgan Stanley sell rating
• Negative Sentiment: Analysts and coverage note margin contraction in Q4 (strong top‑line growth but pressured margins), which is tempering enthusiasm and may explain intraday weakness despite upgrades. Zacks: margins down despite beat

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.